Divis Laboratories Ltd Share Price Today - Divis Laboratories Ltd Stock Price Live NSE/BSE

Divis Laboratories Ltd

NSE: DIVISLAB BSE: 532488

₹6710.50

(0.12%)

Sun, 17 May 2026, 08:50 am

MTF 5xInvest in Divis Laboratories Ltd with 5x Leverage Buy with MTF

Market Cap1781B

PE Ratio71.86

Dividend0.45

Health Technology

Pharmaceuticals: Major

24.5K

Divis Laboratories Share Price Live Chart

1 Day

(0.12%)

No Result Found

Summary

Market Cap
179485.96
Net Profit
2191
P/B
10.22
Sector P/E
35.36
P/E
69.82
EV/EBITDA
44.95
Debt/Equity (Industry)
0.17
Interest Cover (Industry)
18.19
ROCE (Industry)
20.67
RONW (Industry)
17.71
ROE
15.35
ROCE
20.42
Debt/Equity
0
EPS (TTM)
95.43
Dividend Yield
0.44
Book Value
580.60
Interest Cover
973

Analysis

all

Pros

Dividends per share have increased over the past 10 years.
Dividends paid are well covered by earnings (3.2x coverage).
Dividends after 3 years are expected to be well covered by earnings (3.1x coverage).
Dividends per share have been stable in the past 10 years.
Divi's Laboratories's earnings growth is expected to exceed the India market average.

Cons

Divi's Laboratories's pays a lower dividend yield than the bottom 25% of dividend payers in India (0.76%).
Divi's Laboratories's dividend is below the markets top 25% of dividend payers in India (3.08%).
Cash flow for Divi's Laboratories is expected to increase but not above the 50% threshold in 2 years time.
Divi's Laboratories's earnings are expected to grow by 18.9% yearly, however this is not considered high growth (20% yearly).
Divi's Laboratories's net income is expected to increase but not above the 50% threshold in 2 years time.

Financials

Ratios

Shareholders	MAR 2026	DEC 2025	SEPT 2025	JUN 2025	MAR 2025
Promoters	51.88	51.88	51.89	51.89	51.89
FII	20.29	20.08	19.39	19.74	18.01
DII	19.22	19.28	19.76	19.05	20.71
Public	8.60	8.76	8.96	9.32	9.39
Government	0.00	0.00	0.00	0.00	0.00

Technical Analysis

RSI

64.06

MACD

164.71

50 DMA

6290.23

200 DMA

6297.31

Support and Resistance

Type	R3	R2	R1	PP	S1	S2	S3
Classic	8037.17	7135.17	6818.83	6233.17	5916.83	5331.17	4429.17
Fibonacci	7135.17	6790.60	6577.73	6233.17	5888.60	5675.73	5331.17
Camarilla	6750.55	6667.87	6585.18	6233.17	6419.82	6337.13	6254.45

Pivots Level: Classic

+1804

8037.17

+902

7135.17

+585.67

6818.83

6233.17

Pivot Point

LTP: 6760.50

-316.33

5916.83

-902

5331.17

-1804

4429.17

Moving Average

SMAEMA

Period

Value

10-EMA
6704.99
20-EMA
6570.34
30-EMA
6479.61
50-EMA
6388.08
100-EMA
6327.85
200-EMA
6264.27

Announcement Date	Purpose	Action	Ex Date
11 Feb 2026	board-meetings	Quarterly Results, Nine Months Results
07 Nov 2025	board-meetings	Quarterly Results
25 Jun 2025	dividend	Final Dividend - Rs. - 30	25 Jul 2025
17 May 2025	agm
17 May 2025	dividend	₹30.00 Dividend /Share	25 Jul 2025
02 Jul 2024	dividend	Final Dividend - Rs. - 30	02 Aug 2024
25 May 2024	dividend	₹30.00 Dividend /Share	02 Aug 2024
25 May 2024	agm
11 Jul 2023	dividend	Final Dividend - Rs. - 30	11 Aug 2023
03 Jul 2023	agm

Divis Laboratories Ltd

Cipla Ltd

Dr Reddys Laboratories Ltd

Torrent Pharmaceuticals Ltd

Sun Pharmaceutical Industries Ltd

Lupin Ltd

Divis Laboratories Ltd About

Divis Laboratories is engaged in the manufacture of Active Pharmaceutical ingredients (API’s), Intermediates and Nutraceutical ingredients with predominance in exports.

Industry

Pharmaceuticals - Indian - Bulk Drugs

Founded

1990

Headquarters

CEO

Ramesh B V Nimmagadda

Employees

Contact

Website

http://www.divislabs.com

mail@divislaboratories.com; cs@divislaboratories.c

Phone

91-40-23786300/23786352/400

Location

1-72-23(P)/DIVIS/303 Divi Towe, Cyber Hills Gachibowli, Hyderabad, Telangana, 500032

Year	History
2019	Divi's Laboratories approved an additional investment of $250M towards expansion of production blocks in Unit-I and Unit-II. The 7th USFDA inspection in Unit 2 took place.
2020	Commissioning of new production blocks in DC SEZ at Unit-I and DCV SEZ at Unit-II occurred. US-FDA inspection of Unit-II at Village Chippada, Andhra Pradesh took place. Commencement of commercial production from DCV-SEZ Unit began. Construction of Divi's Laboratories Unit-III Facility near Kakinada commenced.
2021	Ground breaking of the manufacturing plant in Kakinada took place.
2022	Divi's Laboratories received the EHS excellence Award. Divi's Laboratories reached the milestone of being one among the top 3 API manufacturers in the world and one among the top API companies in Hyderabad.
2024	Divi's Laboratories has a global presence in supplying APIs to more than 100 countries.

Client Name	Deal Type	Order Side	QTY	Avg Price	Date
GOLDMAN SACHS BANK EUROPE SE - ODI	block	Buy	33108	6120.5	09 Oct 2025
GOLDMAN SACHS (SINGAPORE) PTE - ODI	block	Sell	33108	6120.5	09 Oct 2025
THE MTBJ LTD.AS TRST FOR GOVERNMENT PENSION INVESTMENT FUND MTBJ400045849	block	Buy	21874	6835	14 Jul 2025
THE MTBJ LTD. AS TRST FOR GOVRNMNT PENSION INVSTMNT FUND MTBJ400045828	block	Sell	21874	6835	14 Jul 2025
PI OPPORTUNITIES AIF V LLP	block	Buy	80324	5979.65	06 Nov 2024
PRAZIM TRADING AND INVESTMENT COMPANY PRIVATE LIMITED	block	Sell	80324	5979.65	06 Nov 2024
NORTHERN LIGHTS FUND TRUST III RONDURE NEW WORLD FUND	block	Buy	43478	3637.7	20 Oct 2023
RONDURE NEW WORLD FUND	block	Sell	43478	3637.7	20 Oct 2023
ISHARES CORE EMERGING MARKETS MAURITIUS CO	block	Sell	209124	3271.4	14 Nov 2022
ISHARES CORE MSCI EMERGING MARKETS ETF	block	Buy	209124	3271.4	14 Nov 2022

Divis Laboratories Ltd News

Divi's Labs Board Meet on May 23 to Approve FY26 Results

Divi's Laboratories has scheduled a Board meeting on May 23, 2026, to approve audited standalone and consolidated financial results for Q4 and FY26, and to consider dividend recommendation.

14 May 2026

companies

Divi's Labs Submits Q4FY26 Compliance Certificate

Divi's Laboratories Limited has submitted its quarterly compliance certificate under SEBI regulations for the quarter ended March 31, 2026, confirming proper dematerialization processes.

06 Apr 2026

companies

Divi's Lab Gets ₹570.51 Cr Tax Assessment Order for FY23

Divi's Laboratories receives draft tax assessment order proposing ₹570.51 crore additions for FY2022-23, primarily related to transfer pricing and corporate tax adjustments. Company plans to appeal.

21 Mar 2026

companies

Divi's Labs Receives Draft Tax Assessment Order

Divi's Laboratories receives draft assessment order from Income Tax Authority proposing additions of Rs.570.51 crores for FY2022-23, primarily related to transfer pricing adjustments.

21 Mar 2026

companies

Divi's Labs Board Meet on Feb 11 for Q3FY26 Results

Divi's Laboratories has scheduled a board meeting on February 11, 2026, to consider and approve Q3FY26 financial results. Trading window remains closed until February 13, 2026.

30 Jan 2026

co actions results

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

Version -5.76

Stocks:

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Explore

Calculators

Popular Calculators

Group Stocks

Others:

NSE BSE CDSL NSDL SEBI MCX MSEI NCDEX NSE IFSC INDIA INX Account Closure Form DP Investor Charter Broker Investor Charter

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800